AKTIPAK
LOE ApproachingNDATOPICALGEL
Approved
Nov 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKTIPAK is a topical gel formulation approved as an NDA by Biofrontera in November 2000. The specific mechanism of action and indication are not disclosed in available data, but the topical route and gel formulation suggest dermatological or localized therapeutic use.
LOE Approaching
Product is in late-stage lifecycle approaching loss of exclusivity; team size and hiring likely minimal or transitional.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
AKTIPAK has zero linked open positions, reflecting its LOE-approaching status and diminished commercial activity. Roles available are primarily maintenance-focused and unlikely to offer growth or advancement opportunities.
Brand ManagerField Sales Representative
Worked on AKTIPAK at Biofrontera? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.